share_log

Is Jiangxi Rimag Group (HKG:2522) Using Too Much Debt?

Is Jiangxi Rimag Group (HKG:2522) Using Too Much Debt?

一脈陽光醫學影像(臨時代碼)(HKG:2522)是否過度使用債務?
Simply Wall St ·  12/07 08:05

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know worries about.' So it seems the smart money knows that debt - which is usually involved in bankruptcies - is a very important factor, when you assess how risky a company is. As with many other companies Jiangxi Rimag Group Co., Ltd. (HKG:2522) makes use of debt. But should shareholders be worried about its use of debt?

霍華德·馬克斯用很好地表達了他對於股價波動的擔憂,他說:「永久損失的可能性是我擔心的風險...我認識的每個實踐投資者都會擔心這個。」因此,明智的資金知道,債務——通常涉及破產——是評估公司風險時非常重要的因素。正如許多其他公司一樣,一脈陽光醫學影像(臨時代碼)也使用債務。但股東們應該擔心公司使用債務嗎?

When Is Debt A Problem?

什麼時候負債才是一個問題?

Debt assists a business until the business has trouble paying it off, either with new capital or with free cash flow. In the worst case scenario, a company can go bankrupt if it cannot pay its creditors. However, a more common (but still painful) scenario is that it has to raise new equity capital at a low price, thus permanently diluting shareholders. Having said that, the most common situation is where a company manages its debt reasonably well - and to its own advantage. The first step when considering a company's debt levels is to consider its cash and debt together.

債務能夠幫助企業,直到企業無法用新資本或自由現金流支付債務。在最糟糕的情況下,如果企業無法償還債權人,它可以破產。然而,更常見的(但仍然痛苦的)情況是,它必須以低價籌集新的股本資金,從而永久性地稀釋股東的所有權。話雖如此,最常見的情況是一家公司合理地管理其債務-並且出於自身利益。考慮公司的債務水平時的第一步是將其現金和債務一起考慮。

What Is Jiangxi Rimag Group's Debt?

一脈陽光醫學影像(臨時代碼)的債務是什麼?

The image below, which you can click on for greater detail, shows that Jiangxi Rimag Group had debt of CN¥265.4m at the end of June 2024, a reduction from CN¥358.2m over a year. However, it does have CN¥322.5m in cash offsetting this, leading to net cash of CN¥57.2m.

下面的圖片顯示,您可以點擊查看更詳細信息,顯示一脈陽光醫學影像(臨時代碼)於2024年6月底的債務爲人民幣26540萬,較一年前的人民幣35820萬有所減少。然而,它有人民幣32250萬的現金來抵消這部分債務,導致淨現金爲人民幣5720萬。

big
SEHK:2522 Debt to Equity History December 7th 2024
SEHK:2522債務與股本歷史記錄2024年12月7日

How Healthy Is Jiangxi Rimag Group's Balance Sheet?

一脈陽光醫學影像(臨時代碼)的資產負債表表現如何?

We can see from the most recent balance sheet that Jiangxi Rimag Group had liabilities of CN¥373.5m falling due within a year, and liabilities of CN¥242.4m due beyond that. Offsetting these obligations, it had cash of CN¥322.5m as well as receivables valued at CN¥436.7m due within 12 months. So it can boast CN¥143.3m more liquid assets than total liabilities.

我們可以從最近的資產負債表看出,一脈陽光醫學影像(臨時代碼)有一筆當年到期的負債爲人民幣37350萬,以及一筆到期超過一年的負債爲人民幣24240萬。 抵消這些義務的是,它擁有人民幣32250萬的現金,以及價值人民幣43670萬的應收賬款,需在12個月內到期。因此,它擁有比總負債多人民幣14330萬的流動資產。

This state of affairs indicates that Jiangxi Rimag Group's balance sheet looks quite solid, as its total liabilities are just about equal to its liquid assets. So while it's hard to imagine that the CN¥17.2b company is struggling for cash, we still think it's worth monitoring its balance sheet. Simply put, the fact that Jiangxi Rimag Group has more cash than debt is arguably a good indication that it can manage its debt safely.

事實表明,一脈陽光醫學影像(臨時代碼)的資產負債表看起來相當穩固,因爲其總負債幾乎等於其流動資產。 因此,雖然很難想象這家總資產爲172億人民幣的公司會缺現金,但我們仍認爲值得監控其資產負債表。 簡而言之,一脈陽光醫學影像(臨時代碼)持有的現金多於債務,可以說是一個良好的跡象,表明它可以安全地管理債務。

Shareholders should be aware that Jiangxi Rimag Group's EBIT was down 89% last year. If that decline continues then paying off debt will be harder than selling foie gras at a vegan convention. There's no doubt that we learn most about debt from the balance sheet. But it is future earnings, more than anything, that will determine Jiangxi Rimag Group's ability to maintain a healthy balance sheet going forward. So if you're focused on the future you can check out this free report showing analyst profit forecasts.

股東應意識到,一脈陽光醫學影像(臨時代碼)去年的稅息前利潤(EBIt)下降了89%。 如果這種下降持續下去,那償還債務會比在純素食者大會上出售鵝肝更困難。 毫無疑問,我們從資產負債表中獲取的關於債務的信息最多。 但更重要的是,將決定一脈陽光醫學影像(臨時代碼)未來業務能否保持健康資產負債表的是未來收入。 因此,如果您關注未來,可以查看這份免費關於分析師盈利預測的報告。

Finally, a company can only pay off debt with cold hard cash, not accounting profits. While Jiangxi Rimag Group has net cash on its balance sheet, it's still worth taking a look at its ability to convert earnings before interest and tax (EBIT) to free cash flow, to help us understand how quickly it is building (or eroding) that cash balance. During the last two years, Jiangxi Rimag Group burned a lot of cash. While investors are no doubt expecting a reversal of that situation in due course, it clearly does mean its use of debt is more risky.

最後,一家公司只能用冰冷的現金償還債務,而不是用會計利潤。 儘管一脈陽光醫學影像(臨時代碼)的資產負債表上有淨現金,但仍然值得看一看它將息稅前利潤(EBIT)轉化爲自由現金流的能力,以幫助我們了解其建立(或侵蝕)現金餘額的速度。 在過去兩年中,一脈陽光醫學影像(臨時代碼)燒掉了大量現金。 雖然投資者無疑希望該情況將很快逆轉,但這顯然意味着其使用債務更具風險。

Summing Up

總之

While we empathize with investors who find debt concerning, you should keep in mind that Jiangxi Rimag Group has net cash of CN¥57.2m, as well as more liquid assets than liabilities. Despite its cash we think that Jiangxi Rimag Group seems to struggle to grow its EBIT, so we are wary of the stock. When analysing debt levels, the balance sheet is the obvious place to start. But ultimately, every company can contain risks that exist outside of the balance sheet. Case in point: We've spotted 2 warning signs for Jiangxi Rimag Group you should be aware of.

儘管我們對發現債務令人擔憂的投資者表示同情,但您應該記住,一脈陽光醫學影像(臨時代碼)的淨現金爲5720萬人民幣,流動資產多於負債。 儘管有現金,我們認爲一脈陽光醫學影像(臨時代碼)似乎在努力增長EBIt,所以我們對這支股票持謹慎態度。 在分析債務水平時,資產負債表是開多的地方。 但從長遠來看,每家公司都可能存在超出資產負債表之外的風險。 一例爲:我們發現了一脈陽光醫學影像(臨時代碼)的2個警示信號,您應該注意。

When all is said and done, sometimes its easier to focus on companies that don't even need debt. Readers can access a list of growth stocks with zero net debt 100% free, right now.

當一切塵埃落定時,有時更容易專注於那些甚至不需要債務的公司。讀者可以立即免費查看零淨債務的成長股列表。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論